Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

19.03.2025

Oxford BioTherapeutics Announces That Partner Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments

09.01.2025

Oxford BioTherapeutics To Present at World ADC Conference 2024

30.10.2024

Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024

22.07.2024

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

07.03.2024

Oxford BioTherapeutics Announces First Patient Dosed With OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

18.01.2024

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

29.11.2023

Oxford BioTherapeutics Announced Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial With BI 764532 in Small Cell Lung Cancer and Other Neuroendocrine Cancers

24.10.2023